2023-2029 is the forecast period in the market report.
Cellular reprogramming tools have great potential in regenerative medicine. Cellular reprogramming tools possess the powerful potential and ability to form different types of human cells such as heart, liver, neuron and pancreatic cells. Cell reprogramming tools offer a selection of non-integration reprogramming technologies and services tailored to research and translation needs.
The global Cell Reprogramming market is mainly driven by the growing interest of scientists and researchers in the field of human cell development and innovation. In addition, increasing government funding, increasing industry focus on cell reprogramming and related research, and people's awareness of cell reprogramming and stem cell tools are expected to further drive the market during the forecast period. Factors, such as the advancements in stem cell biology and regenerative medicine to provide viable treatments and the increasing applicability of cell reprogramming in the healthcare sector, are also anticipated to provide ample new growth opportunities for the market in the upcoming years.
In the year 2020, WHO had estimated the prevalence of chronic diseases to be around 57%. The growing acceptance of stem cell therapies for various diseases is expected to positively influence the growth of the industry. For example, blood stem cells are currently used each year in Europe to treat around 26,000 patients. Furthermore, the growing demand for reprogramming of stem cells or cell-based drugs is expected to drive the market during the forecast period.
Stem cell therapy providers are increasing their investment in research and development to accelerate the development of new treatments and therapies. Increased government investment is another incentive for induced pluripotent stem cells (iPSC) providers to expand their research scope. The induced pluripotent stem cell manufacturers are expected to employ various strategies to increase their revenue generation potential across the regions over the forecast period. Additionally, growing medical tourism and research outsourcing will help take the market to the next level. On the other side, rapid progress in developing countries in the field of stem cell research is expected to drive the growth of the market during the estimated time period.
The market is expected to have new opportunities with the technological advancements and ongoing R&D activities involved in cell reprogramming, which is expected to provide ample new growth opportunities for the market during the forecast period. Also, pharmaceutical industry is expected to make extensive use of the iPSC approach to generate efficient cell sources such as functional cells derived from iPSC to enable drug screening and toxicity assessment, which will increase the demand for the technology of cell reprogramming. New players are entering the market with sophisticated technologies to meet growing demand and explore untapped avenues in the industry, and this factor is expected to create new growth opportunities for the market over the forecast period.
The market has major restraints like low efficiency of cell reprogramming and variations in gene expression profiling, which can hamper market growth. Also, the high capital investment and costs involved in stem cell research and development projects are a key factor that is expected to act as a hurdle for the market’s growth over the forecast period. Besides, lack of a skilled workforce is another factor restraining market growth.
There is a significant level of bureaucratic restrictions involved in the use of different cellular reprogramming tools. Also, the high cost of advanced equipment involved in stem cell research along with stringent regulatory standards is expected to be a major hamper to the market’s growth over the forecast period.
The report provides an in-depth analysis of the global Cell Reprogramming market, market size, and compound annual growth rate (CAGR) for the forecast period of 2023-2029, considering 2022 as the base year. With increasing demand for various cell reprogramming tools in various applications has led the increasing demand for market and is expected to witness the growth at a specific CAGR from 2023-2029.
The global Cell Reprogramming market comprises of different market segments like product, technology, application, end users and geography.
By product, the Cell Reprogramming market includes the key segments of
Induced pluripotent stem cells segment is expected to dominate the market over the forecast period. Induced pluripotent stem cells (iPSCs) are derived from skin or blood cells that have been reprogrammed into an embryonic pluripotent state, allowing the development of an unlimited source of any type of human cell needed for therapeutic purposes. The unique properties of iPSC cells offer considerable potential for multiple biopharmaceutical applications. The iPSCs are also used in toxicology testing, broadband, disease modeling, and target identification. This type of stem cell has the potential to transform drug discovery by providing physiologically relevant cells for tool discovery, compound identification and target validation. It is a new medical procedure for the treatment of cardiac arrhythmia as well as liver, prostate, kidney, lung and other types of cancer.
On the other side, the human embryonic stem cells segment is expected to witness significant growth over the forecast period. Human embryonic stem cells are used in the treatment of diabetes and heart disease. The cells are being studied to be used as clinical therapies, models of genetic disorders, and cellular/DNA repair.
By technology, the Cell Reprogramming market is segmented into
The mRNA technology segment is expected to maintain its dominance over the estimated time period. This technology is easy to use and provides a fast, safe and effective way to produce the highest quality human iPSC cells from body tissue. It also offers 1% better reprogramming efficiency and an advantage when working with samples that are difficult to reprogram. For example, according to an article published in February 2022, reprogramming synthetic mRNA cells is an accurate and reliable method for generating human iPSCs.
Also, the Sendai virus-based reprogramming segment is also expected to grow significantly over the projected time period. It generates cellular reprogramming at a constant rate and has technological superiority over other techniques, has a high acceptance rate among patients and is widely used in gene therapy and vaccine administration clinical trials.
The Cell Reprogramming market has key applications in
The research segment is expected to lead the market over the forecast period. One of the key drivers of segment growth is an area of ongoing research in stem cell reprogramming. Governments and other private groups are funding major stem cell research, pushing industry players to conquer their niche in the global industry by treating a range of chronic conditions. For example, 64% of Americans support federal funding for chronic disease research using human embryonic stem cells. Therefore, research efforts are expected to complement the growth of the segment.
The drug development segment is also expected to grow significantly over the forecast period. Cellular reprogramming has already opened up incredible possibilities for therapeutics such as new drug treatments that either inhibit degenerative changes or encourage stem or progenitor cells to recognize the difference in lineage affected in a given condition, both of which are possible following reprogramming studies. Certain degenerative diseases can also be treated by cell transplantation. The speed and scale of these developments are driving the growth of the segment.
The Cell Reprogramming market has major end users like
The research and academic institutions segment is expected to dominate the market over the forecast period. Cellular reprogramming has been used in numerous clinical and academic research projects, including those involving regenerative medicine, disease modeling, and drug toxicity / drug discovery studies. The growth of the segment is also driven by an increase in the number of efforts in strategic discovery and efforts for innovative cell reprogramming products.
The biotechnology and pharmaceutical companies segment is expected to witness considerable growth over the forecast period. The pharmaceutical industry is expected to broadly adopt the iPSC approach to generate effective cell sources, such as iPSC-derived functional cells, to enable drug screening and toxicity assessment, thereby increasing the demand for cell reprogramming technology.
The global Cell Reprogramming market is studied for the following regions
North America is expected to dominate the market and experience high growth rate over the forecast period. The high growth can be attributed to the current IPSC technological progress and the availability of functional cells for pre-clinical pharmacological tests. The high-level analysis of medicines and the expansion of knowledge on the IPSC platform both contribute to the expansion of the market in the region.
Asia-Pacific is expected to be the fastest growing region due to improvements in manufacturing and efficiency in the therapeutic landscape. The COVID-19 pandemic has further fuelled market growth in Asia Pacific owing to the large patient population and currently there is no effective treatment for the infection especially in severe cases.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the global Cell Reprogramming market. In addition, complete analysis of changes on the global Cell Reprogramming market expenditure, economic and international policies on supply and demand side. The report also studies the impact of the pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market.
The outbreak of Covid-19 has led to an increase in the use of cells and its programming methods for the production of personalized medicines. In March 2022, for example, an important cell programming phase that made the screening of safe drugs and other personalized disease therapy possible, identified and described by the bioengineers and the members of UCLA, which also play an important role in the development of new medicines and personalized medicines.
In addition, researchers are working on the development of new medicines and treatments to fight this pandemic. In this situation, IPSC are effective research resources for creating normal and relevant cell types for Sars-Cov-2. Furthermore, the creation of physiologically specific human cell models that can mimic the pathophysiology of COVID-19 using iPSC is critical for facilitating drug testing and has captured the attention of pharmaceutical companies interested in rapidly delivering drugs through the use of cellular reprogramming.
The competitive landscape analysis of Cell Reprogramming market is majorly focused on expanding the global growth of cell reprogramming industry with new product innovation, business expansion, increasing presence of range of manufacturer operating in cell reprogramming sector has led the growing demand for the market. Besides, the market offers a range of products in different applications to fulfil the required demand of consumers, which is further contributing to healthy growth in the market.
The key players studied in market are
April 2023: Ncardia had announced the opening of a new company named Cellistic to help the iPSC reprogramming industry expansion.
April 2022: Tidal Therapeutics was acquired by Sanofi. In addition, Sanofi’s research capabilities in immuno-oncology and inflammatory disorders will be enhanced by the new technology platform, which is also probably broadly applicable to other disease areas.
By product, the Cell Reprogramming Market includes the key segments of adult stem cells, human embryonic stem cells, induced pluripotent stem cells, and small embryonic like stem cells. Induced pluripotent stem cells segment is expected to dominate the market over the forecast period.
By technology, the Cell Reprogramming market is segmented into sendai virus-based reprogramming, mRNA reprogramming, episomal reprogramming and others. The mRNA reprogramming segment is expected to maintain its dominance over the estimated time period. The Cell Reprogramming market has key applications in research, therapeutic, drug development, regenerative medicine and toxicity testing. The research segment is expected to find increasing demand in the market over the forecast period. The Cell Reprogramming market has major end users like research and academic institutes, biotechnology and pharmaceutical companies, hospitals and clinics. The research and academic institutions segment is expected to dominate the market over the forecast period. The global Cell Reprogramming market is studied for the following regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). North America is expected to dominate the market and is expected to experience high growth over the forecast period.
|Market Sizing for Year:||2019-2029|
|Market Segment studied:|
|Market Players and its Competitors:|
Thermo Fisher Scientific
Advanced Cell Technology, Inc.
Applied Biological Materials
Fujifilm Cellular Dynamics
Mesoblast LtdHuman Longevity, Inc
What would be forecast period in the market report?
2023-2029 is the forecast period in the market report.
Which is the leading application segment for Cell Reprogramming market?
The research application has accounted the major market share, and is expected to witness the growth at highest pace during the forecast period.
Which region is gaining majority of market share during the forecast period (2023-2029)?
North America is expected to gain major market share during the forecast period (2023-2029).